Polycystic ovary syndrome (PCOS) affects about 1 in 8 women worldwide. For years, patients and doctors have said the name was confusing and misleading. Now, after a large international effort, PCOS has officially been renamed polyendocrine metabolic ovarian syndrome (PMOS).
This change followed a structured global consensus process designed to better reflect the science, reduce stigma, and improve diagnosis and care .
Why the Name PCOS Needed to Change
The term “polycystic ovary syndrome” suggests that the condition is mainly about ovarian cysts. In reality, women with this condition do not have harmful cysts. Instead, the ovaries often contain many small follicles that are part of disrupted hormone signaling; however they are not true cysts.
More importantly, the condition affects much more than the ovaries. Research has shown that it involves multiple hormone systems and has wide effects across the body . These include:
- Hormone imbalances, especially insulin and androgens
- Metabolic problems such as insulin resistance and higher risk of type 2 diabetes
- Irregular periods and ovulation problems
- Fertility challenges
- Skin changes like acne or excess hair growth
- Increased risk of cardiovascular disease
Because the name focused narrowly on ovaries and “cysts,” it often led to misunderstanding. Many women experienced delayed diagnosis, fragmented care, and stigma—especially in cultures where fertility carries strong social meaning. Studies have shown that up to 70% of affected individuals may remain undiagnosed.
Experts and patient groups had called for change for years. The evidence was clear: the name no longer matched the science.
How the Global Name Change Was Decided
The shift to PMOS did not happen quickly. It followed a rigorous, multistep international process.
The initiative involved:
- Engagement of 56 academic, clinical, and patient organizations
- Two large global surveys
- Formal consensus workshops
- Marketing and implementation analysis
In total, 14,360 people participated, including more than 10,000 patients and nearly 4,000 health professionals from all world regions .
Participants agreed that the new name had to meet several principles. It needed to:
- Reflect scientific accuracy
- Avoid stigma
- Be clear and understandable
- Be culturally appropriate
- Be practical to implement worldwide
After multiple rounds of surveys and workshops, the final name chosen was polyendocrine metabolic ovarian syndrome (PMOS) .
What the New Name Means
Each word in PMOS was carefully selected to reflect the condition’s true biology.
Polyendocrine highlights that multiple hormone systems are involved. This includes insulin, ovarian hormones, adrenal hormones, and brain hormone signaling. The condition is not limited to one gland.
Metabolic recognizes that insulin resistance and metabolic dysfunction are central features. Many women with PMOS have increased risks of:
- Type 2 diabetes
- High blood pressure
- Abnormal cholesterol
- Cardiovascular disease
Research shows these metabolic features are not secondary but they are core to the condition.
Ovarian remains important because ovarian dysfunction is still a defining part of the syndrome. Women may experience disrupted ovulation, irregular menstrual cycles, and fertility challenges.
The word “cyst” was intentionally removed because it inaccurately suggested a structural ovarian disease rather than a hormonal disorder.
Why This Change Matters for Women’s Health
The authors of the Lancet Health Policy paper emphasize that this is more than a simple rebranding . Aligning the name with modern science can:
- Improve awareness among clinicians
- Support earlier diagnosis
- Enhance patient understanding
- Strengthen research consistency
- Improve policy alignment and health system coding
The change also reduces stigma tied to fertility and reproduction. By emphasizing endocrine and metabolic health, the name better reflects that this is a whole-body condition affecting women across their lifespan—not only during reproductive years.
How the Transition Will Happen
The implementation plan is already underway. It includes updates across:
- Medical guidelines
- Educational materials
- Electronic health records
- Research funding and classification systems
- International disease coding
A structured three-year transition period has been planned to allow global adoption. The International Guideline, used in 195 countries, will formally integrate PMOS in its next update.
The Bottom Line
More than 170 million women worldwide live with this condition . For decades, the name did not reflect the full scope of the disease or the lived experience of patients.
Polyendocrine metabolic ovarian syndrome better captures the complex hormone and metabolic pathways involved. The goal is simple: clearer understanding, earlier diagnosis, better care, and improved long-term health outcomes.
Source:
Teede HJ, Bahri Khomami M, Morman R, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet. 2026; published online May 12. doi:10.1016/S0140-6736(26)00717-8. Accessed by: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00717-8/fulltext
